Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network.

Authors

Carissa Jones

Sarah Cannon Research Institute, Nashville, TN

Carissa Jones , Rebecca Lachs , Emma Sturgill , Amanda Misch , Caressa Lietman , Suzanne Fields Jones , Melissa Lynne Johnson , David R. Spigel , Andrew Jacob McKenzie

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.

First Author: Jeffrey A. Scott

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study.

First Author: Robert E. Smith

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC.

First Author: David Chun Cheong Tsui

insert_chart_outlined

Poster

2023 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).

First Author: Ruchit Shah